title: [A case of advanced lung adenocarcinoma with cavity formation shrunken by bevacizumab added on the 3rd course of 6th-line chemotherapy].
abstract: A 65-year-old man was pointed out to have an abnormal lung shadow by chest radiograph in a medical examination in 2007. An extensive examination diagnosed him as a case of advanced lung adenocarcinoma. He was treated by chemotherapy up to the 5th-line(cisplatin+docetaxel→CPT-11+S-1→amrubicin→gemcitabine+vinorelbine→pemetrexed), and the evaluation after the 5th-line treatment revealed disease progression. As he still maintained good performance status, the 6th- line treatment with carboplatin(AUC6, day 1)+paclitaxe(l 200mg/m2, day 1)(Q3W)was administered in March, 2010. The tumor size had been increasing slightly after 2 courses of chemotherapy, although it was within the range of stable disease. Therefore, bevacizumab(15mg/kg, day 1)was added after the 3rd course of treatment, and the tumor began shrinking obviously with cavity formation. Although the positioning of bevacizumab has not been established after 2nd-line treatment for advanced non-small cell lung carcinoma, we experienced a case of good tumor response by adding the bevacizumab in the middle of the 6th-line chemotherapy.
authors.affiliation: Dept. of Internal Medicine, Keio University School of Medicine, Japan.
authors.forename: Masaki
authors.initials: M
authors.lastname: Miyazaki
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Naoki
authors.forename: Takashi
authors.initials: T
authors.lastname: Sato
authors.forename: Kyuto
authors.initials: K
authors.lastname: Tanaka
authors.forename: Keishi
authors.initials: K
authors.lastname: Tsuzuki
authors.forename: Shuichi
authors.initials: S
authors.lastname: Yoshida
authors.forename: Katsuyoshi
authors.initials: K
authors.lastname: Tomomatsu
authors.forename: Sadatomo
authors.initials: S
authors.lastname: Tasaka
authors.forename: Kenzo
authors.initials: K
authors.lastname: Soejima
authors.forename: Koichi
authors.initials: K
authors.lastname: Sayama
authors.forename: Koichiro
authors.initials: K
authors.lastname: Asano
mesh_terms: D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D000077192:Adenocarcinoma of Lung; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D009367:Neoplasm Staging; D035422:Pleural Cavity; D016879:Salvage Therapy; D014057:Tomography, X-Ray Computed
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab